Hormone-Dependent Prostate Cancer: An Evaluation of Current and Emerging Novel Therapies
A significant portion of patients with hormone-dependent prostate cancer fail to reach castrate levels of androgens after hormonal therapy, and controversy exists regarding the appropriate level. Furthermore, a significant percentage of healthcare professionals do not measure serum testosterone routinely. They need to be educated and remain aware of specific clinical issues around the management and monitoring of prostate cancer and evaluate the risks and benefits of the type and duration of androgen ablation treatment in each patient on an individual basis.

Upon completion of this activity, participants should be better able to:

• Explain the current treatment options used for patients with hormone-dependent prostate cancer such as luteinizing hormone-releasing hormone (LHRH) agonists and gonadotropin-releasing hormone (GnRH) antagonists
• Describe the clinical importance of monitoring testosterone levels in patients who are on LHRH analog therapy and maintaining optimal levels of testosterone suppression
• Review the historical criteria for determining the adequacy of androgen suppression and evaluating data that requires a reassessment of these historical and regulatory data
• Review hormonal events such as testosterone surge, breakthrough increase, and clinical flare that can occur during LHRH therapy and their clinical significance
• Specify the risks and benefits of treatment strategies used for patients with hormone-dependent prostate cancer

» Go to this activity

You are subscribed to ModernMedicine.com. To unsubscribe, click here

To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.